Novo Nordisk Submits IND Application for Oral PCSK9 Inhibitor NNC0385-0434 in China

On June 30, the CDE website indicated that the clinical trial application for Novo Nordisk's oral PCSK9 inhibitor, NNC0385-0434 tablets, has been accepted by the National Medical Products Administration (NMPA). This product is the third oral PCSK9 inhibitor to be submitted for clinical trials in China.